In SSc, TGFβ blockade with fresolimumab, a pan-TGFβ inhibitor, yielded mixed results, showing modest anti-fibrotic benefits in some studies but failing to meet primary endpoints in others, along with raising safety concerns (61). This evidence concerns the gene TGFB1 and systemic sclerosis.